Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

55.6%

-31.0% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(33.3%)

Phase 2

3(33.3%)

Phase 3

3(33.3%)

9Total

Phase 1(3)

Phase 2(3)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00563433Phase 3Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Role: collaborator

NCT00563394Phase 3Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Role: collaborator

NCT00606112Phase 1Completed

A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

Role: lead

NCT00806338Phase 1Completed

An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

Role: lead

NCT00094120Phase 2Terminated

MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Role: lead

NCT00509132Phase 1Completed

A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers

Role: lead

NCT00139282Phase 3Terminated

A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration

Role: lead

NCT00333476Phase 2Terminated

A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Role: lead

NCT00089830Phase 2Terminated

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Role: lead

All 9 trials loaded